Penn Medicine Provider
Renal Electrolyte and Hypertension
Ellie Kelepouris, MD
4.9
(87)
Accepting new patients
Sees patients age 18 and up
Penn Renal Electrolyte and Hypertension Perelman
Schedule onlineCall 215-662-2638

About me

  • Director, Outpatient Dialysis Programs
  • Professor of Clinical Medicine (Renal-Electrolyte and Hypertension)

Education and training

  • Medical School: University of Athens
  • Residency: Mercy Fitzgerald Hospital
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

87 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
it's good to know and have a physician who cares, is knowledgeable in her particular field and can present and explain your care and needs to you in a way that doesn't offend you or make you feel inferior or inadequate in other words so that you are able to take care of yourself to the best of your abilities comfortably. it's all in the way you handle each individual person and in their own unique way in their situation at the time. you never know what that person is going through because they may not be able to really open up and tell you. bedside manner is important and my provider is excellent.
April 2025
5.0
5.0
very professional
April 2025
5.0
5.0
the doctor was attentive , compassionate and paid attention to detail.
March 2025
5.0
5.0
i felt very confident with my dr.

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Kelepouris is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Quinn, G., Greene, S, Sauer, A., Anker, S.D., Bohm, M., Bozkurt, B., Butler, J., Cleland, J.G., Coats, A.J.S., Desai, N., Pinto, F., Rosano, G., Brandes, C, M, Donachie, V., Kelepouris, E. Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalemia barrier? , European Society of Cardiology: Heart Failure Association. Belgrade, Serbia: 2025,16-20

Martinez, O.C., Greene, S., Anker, S, Bozkurt, B, Butler, J., Cleland, J.G., Desai, N, Grobbee, D, Kelepouris, E. Rosano, G, Brandes, C.M., Donachie, V, Sauer, A. Real-world use and effectiveness of patiromer among patients with heart failure at high risk of hyperkalemia: insights from the CARE-HK in HF registry , European Heart Failure Association - Belgrade, Serbia: 2025

G. Quinn, S.J. Greene, A.J. Sauer, S.D. Anker, M. Bloom, B. Bozkurt, J. Butler, J.G.F. Cleland, A.J.S. Coats, N.R. Desai, F. Pinto, G. Rosano, Brandes, C-M, V. Donachie and Kelepouris, E. Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalemia a barrier? , European Heart Failure Association, Belgrade, Serbia: 2025

Kelepouris, E., Desai, N., Kosirobod, M., Budden, J., Boehm, M. Collaborative Management o Hyperkalemia in Patients with Complex Heart Failure. , Case Reports in Nephrology and Dialysis, Case Reports: 2025

Martinez, O.C., Greene, S., Anker, S., Bozkurt, B., Butler, J., Cleland, J.G., Desai, N., Grobbee, D., Kelepouris, E., Rosano, G., Brandes, C.M., Donachie, V., Sauer, A. Real-world use and effectiveness of patiromer among patients with heart failure at high risk of hyperkalemia: insights from the CARE-HK in HF registry , EHA: 2025

E. Kelepouris, N. Desai, K.A.A. Clark, M.N. Kosiborod, J. Budden, S. Waechter, and M. Bohm Collaborative management of hyperkalemia in patients with complex heart failure , Journal Case Reports in Nephrology and Dialysis: 2024

Rastogi A, Chertow GM, Collins A, Kelepouris E, Kotzker W, Middleton JP, Rajpal M, Roy-Chaudhury P. Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists , Adv Kidney Dis Health, 31(6): 2024,514-522

A. Rastogi, A. Collins, E. Kelepouris, W. Kotzker, J.P. Middleton, M. Rajpal, P. Roy-Chaudhury and G.M. Chertow Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists , Journal of Primary Care and Community Health , 15: 2024,21501319241259905

S.J. Greene, M. Bohn, B. Bozkurt, J. Butler, J.G.F. Cleland, A.J.S. Coats, N.R. Desai, D.E.Grobbee, E. Kelepouris, F. Pinto, G. Rosano, I. Morin, P. Szecsody, S. Fabien, S. Waechter, M.G. Crespo-Leiro, M. Hulsmann, T. Kempf, O. Pfister, A-C Pouleur, A.J. Sauer, M. Saxena, M. Schulz, M. Volterrani, S.D. Anker and M. Kosiborod Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalemia or high risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry , J. of Cardiac Failure, 00: 2024,1-11

Kelepouris, E. Rovin, B Approach to the patient with Nephrotic Syndrome , Up to Date: 2024